An interventional study of Opioid Stewardship Program in Pain, Chronic Pain and Opioid Analgesia, sponsored by Korea University Guro Hospital. Recruiting at 1 site in South Korea. Open to participants aged 19 Years to 79 Years. Per ClinicalTrials.gov, last updated 2025-08-03.
Sponsored by Korea University Guro Hospital · Not applicable, Interventional, and Health services research
Among 36 studies in Chronic Pain with a site in Korea, Republic of — 10 open to participants now, 11 under way, none of them phase 3. Chronic Pain · Korea, Republic of.
Among the 36 studies in Chronic Pain with a site in Korea, Republic of, this one is the 15th largest by planned enrollment of the 28 interventional ones that give a count, is one of 3 that started in 2025, is one of 22 with no phase, reaches primary completion later than 4 of the 10 other live ones, and was the 34th registered.
3,227 studies on the registry are indexed under Chronic Pain; 728 are open to participants now.
Browse Chronic Pain studies →10 of the 36 studies in Chronic Pain with a site in Korea, Republic of are open now. Recruiting first, the newest first:
Jaseng Medical Foundation · Sites in Korea, Republic of
Ages 19–70
Korea University · Sites in Korea, Republic of
Ages 60+ · Healthy volunteers
Keimyung University Dongsan Medical Center · Sites in Korea, Republic of
Ages 20–80
Sahmyook University · Sites in Korea, Republic of
Jeeyoun Moon · Sites in Korea, Republic of
Ages 19+
A study can be open while its sites in Korea, Republic of have not opened yet or have stopped. Only those recruiting at a site in Korea, Republic of →
Of the 486 Chronic Pain studies recruiting now, 239 (49%) set no upper age limit and 173 (36%) stop at 75 or younger; 43 take children under 18; 64 take healthy volunteers.
This study: 19 Years to 79 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
36 studies; the count open now beside each. This study's row is marked.
First in 2005; this study’s year is marked. 3 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 70 is above the median of 60 across 2,387 interventional studies indexed under Chronic Pain.
Median enrollment 76 across the 28 interventional studies, 89 across the 8 observational. Of the 17 that completed or were terminated, 5 (29%) have results posted.
This tab as a report to print or save as PDF → With an account.
8 of 36 have an industry lead sponsor. The 10 most frequent:
Korea University Guro Hospital is the lead sponsor of 89 studies on the registry; 17 are open to participants now.
Korea University Guro Hospital has 1 study filed under Chronic Pain — fewer than ten, so there is no comparison to draw.
4 of the studies in Chronic Pain with a site in Korea, Republic of that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06270121Sunmi SongDevelopment of a Healthcare Service Platform for Successful Aging | 2026-11-30 |
| NCT07832318Jaseng Medical FoundationEffectiveness and Safety of Pharmacopuncture Therapy for Chronic Lumbar Radiculopathy: A Multicenter, Pragmatic, Randomized, Comparative Clinical Trial | 2026-12 |
| NCT07917702Gwangju Health UniversityEffects of Transcranial Direct Current Stimulation and Manual Therapy on Musculoskeletal Pain in Adolescent Dancers | 2026-12-09 |
| NCT07485387Korea UniversityGlobal Collaborative Research on Establishing a Korean Cognitive Aging Cohort | 2027-04-30 |
Add all 4 to your calendar (.ics) → With an account.
Among the 36 studies in Chronic Pain with a site in Korea, Republic of, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The objective of this prospective, non-randomized clinical trial is to evaluate the effectiveness of a pharmacist-led Opioid Stewardship Program (OSP) in outpatient adults with chronic non-cancer pain. This study compared OSP implementation with a historical control to determine whether it reduces the incidence of high-risk opioid prescribing and improves patients' awareness, knowledge, and attitudes about opioid use.
3,227 studies on the registry are indexed under Chronic Pain; 728 are open to participants now.
This study's planned enrollment of 70 is above the median of 60 across 2,387 interventional studies indexed under Chronic Pain.
Browse Chronic Pain studies →Korea University Guro Hospital is the lead sponsor of 89 studies on the registry; 17 are open to participants now.
Compared within Chronic Pain, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Pain. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants in this arm are adult outpatients with chronic non-cancer pain who receive a pharmacist-led Opioid Stewardship Program (OSP) for their chronic opioid use.
Other: Opioid Stewardship Program
The Opioid Stewardship Program (OSP) includes pain and functional assessments, opioid prescription review and coordination, patient education, and counseling provided by trained pharmacists.
Incidence of potentially high-risk opioid prescriptions
This outcome measures the proportion of potentially high-risk opioid prescriptions based on predefined criteria: * Prescription (Rx) of ER/SR opioids to patients with no prior opioid use * Rx of certain ER/SR opioid dosages to patients who are not opioid-tolerant * Rx of sublingual/buccal fentanyl * Rx exceeding 50 MME/day * Rx exceeding 10 MME/dose or 30 MME/day to patients with no prior opioid use * Rx with no dose adjustments for the elderly or renally impaired with no prior opioid use * ER/SR opioid conversions outside 50-75% of the prior MME/day * Rx of oral ER/SR opioids more than twice daily * Rx of transdermal fentanyl at intervals less than 72 hours * Rx exceeding 30 days supply * Rx without a pain assessment in the past 3 months in long-term opioid users * No opioid dose adjustment in the last 3 Rx despite additional pain interventions and improved pain in long-term users * No opioid dose adjustment in the last 3 Rx despite the lack of pain improvement in long-term users
Time frame: At each outpatient visit during the study evaluation period (up to 4 months per participant)
Average daily morphine milligram equivalent (MME)
This outcome assesses the clinical effect of the intervention by calculating the average daily MME for each opioid prescription during the study evaluation period.
Time frame: At each outpatient visit during the study evaluation period (up to 4 months per participant)
Change in opioid knowledge scores after education sessions compared to baseline
This outcome evaluates patient understanding of opioid use. Knowledge scores are measured at baseline (before the first education session) and after each of the education sessions using a validated questionnaire.
Time frame: At each outpatient visit during the study evaluation period (up to 4 months per participant)
Change in opioid attitude scores after education sessions compared to baseline
This outcome assesses patient attitudes toward opioid use, including concerns about addiction, side effects, and trust in physicians. Attitude scores are measured at baseline and after each of the education sessions using a modified K-PMAQ-14 (Korean version of pain medication attitude questionnaire-14) survey.
Time frame: At each outpatient visit during the study evaluation period (up to 4 months per participant)
Plan to share: No — The decision not to share individual participant data (IPD) is based on the possibility that the research data may contain personally identifiable information. Informed consent was not obtained from participants for the sharing of their individual data with third parties.
No publications or documents are linked to this record.
Started Jun 2025 (actual). Primary completion is estimated for Dec 2025, 6 months after the start.
Of 1,295 non-industry interventional studies with no phase under Chronic Pain, half reached primary completion within 20 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 39. This study's planned 6 months is below that.
Counting every sponsor, half of 1,378 studies reached it within 20 months; a quarter within 9 and three quarters within 38.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Korea University Guro Hospital